Добірка наукової літератури з теми "Organoïdes dérivé de patients"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Organoïdes dérivé de patients".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Organoïdes dérivé de patients"
Steichen, Clara, Sébastien Giraud, and Thierry Hauet. "Les organoïdes rénaux." médecine/sciences 35, no. 5 (May 2019): 470–77. http://dx.doi.org/10.1051/medsci/2019090.
Повний текст джерелаDusetti, Nelson, and Juan Iovanna. "Organoïdes dérivés des adénocarcinomes pancréatiques." médecine/sciences 36, no. 1 (January 2020): 57–62. http://dx.doi.org/10.1051/medsci/2019259.
Повний текст джерелаLebreton, Fanny, Charles-Henri Wassmer, Kevin Belofatto, Thierry Berney, and Ekaterine Berishvili. "Organoïdes sécréteurs d’insuline." médecine/sciences 36, no. 10 (October 2020): 879–85. http://dx.doi.org/10.1051/medsci/2020129.
Повний текст джерелаPapoz, Anastasia, Flora Clément, Camille Laporte, Emily Tubbs, Xavier Gidrol, and Amandine Pitaval. "Les Langerhanoïdes, des organoïdes d’îlots pancréatiques." médecine/sciences 38, no. 1 (January 2022): 52–58. http://dx.doi.org/10.1051/medsci/2021244.
Повний текст джерелаGodard, P., I. Boucot, C. Pribil, and D. Huas. "Phénotype des patients asthmatiques selon le score dérivé de l’Asthma Control Test®." Revue des Maladies Respiratoires 27, no. 9 (November 2010): 1039–48. http://dx.doi.org/10.1016/j.rmr.2010.09.015.
Повний текст джерелаFlatres, Charlotte, Élise Loffet, Michel Neunlist, and Maxime M. Mahé. "Façonner l’intestin à partir des cellules souches pluripotentes humaines." médecine/sciences 35, no. 6-7 (June 2019): 549–55. http://dx.doi.org/10.1051/medsci/2019096.
Повний текст джерелаVogt. "Der Patient mit Bluterbrechen – wie weiter?" Praxis 91, no. 12 (March 1, 2002): 493–97. http://dx.doi.org/10.1024/0369-8394.91.12.493.
Повний текст джерелаBourbonne, V., M. Vallières, F. Lucia, L. Doucet, V. Tissot, G. Cuvelier, S. Hue, et al. "Validation externe d’un modèle radiomique dérivé de l’IRM pour guider la sélection des patients en vue d’une radiothérapie adjuvante après prostatectomie dans le cadre d’un adénocarcinome prostatique à haut risque." Cancer/Radiothérapie 23, no. 6-7 (October 2019): 791–92. http://dx.doi.org/10.1016/j.canrad.2019.07.011.
Повний текст джерелаGalzin, AM, D. Graham, and SZ Langer. "Systèmes de transport de la sérotonine et antidépresseurs." Psychiatry and Psychobiology 5, no. 3 (1990): 201–7. http://dx.doi.org/10.1017/s0767399x00003503.
Повний текст джерелаДисертації з теми "Organoïdes dérivé de patients"
Seitlinger, Joseph. "Optimisation d’un modèle d’organoïde de cancer du poumon vascularisé dérivé de patient à des fins de médecine de précision." Electronic Thesis or Diss., Strasbourg, 2022. http://www.theses.fr/2022STRAJ022.
Повний текст джерелаDespite numerous recent advances, lung cancer is the leading cause of cancer mortality worldwide. Every year, new therapeutic drugs are developed to fight this disease whose prognosis remains poor. The development of precision medicine should make it possible to improve its effectiveness. In this perspective, we have optimized an organoid model derived from lung cancer patients. In this work, we were able to show that our model is reproducible and that it mimics the patient's tumor. Finally, the formation of a vascular network at the level of the organoid is possible : it can infiltrate the formed organoid but can also grow from the organoid to infiltrate the microenvironment. The model that we put forward thus meets the specifications of a patient Avatar model. The tests of therapeutic drugs or irradiation that we are currently carrying out will allow us to define if this model is compatible with a future use in clinical practice to improve the management of patients diagnosed with lung cancer
Morice, Pierre-Marie. "Evaluation de la déficience de la recombinaison homologue et de la réponse des tumeurs ovariennes aux inhibiteurs de PARP grâce à l'utilisation de modèles de culture 3D en vue du développement d'un test prédictif Identifying eligible patients to PARP inhibitors: from NGS-based tests to promising 3D functional assays Automated scoring for assessment of RAD51-mediated homologous recombination in patient-derived tumor organoids of ovarian cancers Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitors: a combined approach using a safety meta-analysis of placebo randomized controlled trials and the World Health Organization's pharmacovigilance database The long non-coding RNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels." Thesis, Normandie, 2020. http://www.theses.fr/2020NORMC414.
Повний текст джерелаWorldwide each year, more than 150 000 women die from epithelial ovarian cancer largely due to emergence of resistance to chemotherapy. Approximately half of these cancers display molecular alterations that cause deficiency of DNA repair via homologous recombination (HRD), which confer sensitivity to PARP protein inhibitors (PARPi). To date, there is no test capable of fully identifying the HRD phenotype, thus limiting access to these treatments. In this context, we are developing functional assays based on the use of tumor explant slices and then, on the use of tumor organoids derived from ovarian tumors of chemotherapy-naive or previously treated patients. The culture of explants was unsuitable for this application and we then focused our work on tumor organoids. Tumor organoids were exposed to carboplatin (first-line treatment) and two PARP inhibitors (olaparib and niraparib) used for maintenance therapy. In parallel, we collected clinical data from patients (survival, platinum-free interval, RECIST, treatments) to evaluate the predictive potential of these models. The established tumor organoids responded heterogeneously to different drugs, and our results show that the organoid-based assay is capable of identifying patients highly resistant to carboplatin, suggesting that this functional assay could have a predictive value for patients treated with carboplatin. Regarding the potential of organoids in predicting PARPi response, multiple sensitivity profiles have been identified, but the correlation with clinical response has yet to be determined by studies conducted on tumor samples from patients treated with these drugs